Journal article

Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease

Stephanie A Schultz, Jeremy F Strain, Adedamola Adedokun, Qing Wang, Oliver Preische, Jens Kuhle, Shaney Flores, Sarah Keefe, Aylin Dincer, Beau M Ances, Sarah B Berman, Adam M Brickman, David M Cash, Jasmeer Chhatwal, Carlos Cruchaga, Michael Ewers, Nick N Fox, Bernardino Ghetti, Alison Goate, Neill R Graff-Radford Show all

Neurobiology of Disease | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2020

Abstract

Neurofilament light chain (NfL) is a protein that is selectively expressed in neurons. Increased levels of NfL measured in either cerebrospinal fluid or blood is thought to be a biomarker of neuronal damage in neurodegenerative diseases. However, there have been limited investigations relating NfL to the concurrent measures of white matter (WM) decline that it should reflect. White matter damage is a common feature of Alzheimer's disease. We hypothesized that serum levels of NfL would associate with WM lesion volume and diffusion tensor imaging (DTI) metrics cross-sectionally in 117 autosomal dominant mutation carriers (MC) compared to 84 non-carrier (NC) familial controls as well as in a su..

View full abstract

Grants

Awarded by Dominantly Inherited Alzheimer Network (DIAN)


Awarded by National Institute on Aging (NIA)


Awarded by National Science Foundation


Awarded by Medical Research Council Dementias Platform UK


Funding Acknowledgements

Data collection and sharing for this project were supported by The Dominantly Inherited Alzheimer Network (DIAN, UF1AG032438) and K01 AG053454 funded by the National Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), the National Science Foundation (DGE-1745038), the National Institute for Health Research (NIHR), Queen Square Dementia Biomedical Research Centre, and the Medical Research Council Dementias Platform UK (MR/L023784/1 and MR/009076/1). Partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development (AMED), Raul Carrea Institute for Neurological Research (FLENI), and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI). This manuscript has been reviewed by DIAN Study investigators for scientific content and consistency of data interpretation with previous DIAN Study publications. Most of all we acknowledge the altruism of the participants and their families and the contributions of the DIAN research and support staff at each of the participating sites. Without these contributions the research would not be possible.